Home › Compare › SSHPF vs ABBV
SSHPF yields 926.35% · ABBV yields 3.06%● Live data
📍 SSHPF pulled ahead of the other in Year 1
Combined, SSHPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SSHPF + ABBV for your $10,000?
Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, Canada, and Italy. It operates in three segments: Projects Cruise, Aftersales, and Landbased. The Projects Cruise segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; advanced systems to shipowners for ships; and systems for aquaculture sludge treatment. The Aftersales segment provides spare parts and consumables; chemicals; and tailor-made service and maintenance programs. The Landbased segment offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. The company serves cruise, aquaculture, and landbased industries, as well as utilities. It has a strategic partnership agreement with Repsol, S.A. to explore applications and solutions to produce clean and renewable energy for CO2 emission reduction. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was incorporated in 2011 and is headquartered in Lysaker, Norway.
Full SSHPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.